Cullgen, founded by Ying Luo, Ph.D., is a biopharmaceutical company dedicated to developing novel therapies for diseases that currently lack effective treatments. The company's core mission is to revolutionize medicine by leveraging protein degradation technology to selectively target and degrade disease-causing proteins, including those previously considered undruggable. Cullgen's primary focus is on creating innovative treatments for cancer, inflammatory, and autoimmune diseases through their proprietary uSMITE™ platform.
Notable figures affiliated with Cullgen include CEO Ying Luo, Ph.D., who leads the company's vision of expanding the drug design paradigm. Cullgen has garnered attention for its groundbreaking approach to targeted protein degradation, positioning itself as a leader in the biopharmaceutical industry. The company's impact lies in its potential to provide new therapeutic options for debilitating diseases, thereby transforming patient outcomes and advancing medical science.
